Alendronate use and bone mineral density gains in women with moderate-severe (stages 3B–5) chronic kidney disease: an open cohort multivariable and propensity score analysis from Funen, Denmark

SUMMARY: Bisphosphonates are contraindicated in moderate-to-severe chronic kidney disease patients. However, they are used to prevent fragility fractures in patients with impaired kidney function, despite a lack of evidence on their effects on bone density in these patients. We demonstrated that Ale...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali, M. Sanni, Ernst, Martin, Robinson, Danielle E., Caskey, Fergus, Arden, Nigel K., Ben-Shlomo, Yoav, Nybo, Mads, Rubin, Katrine H., Judge, Andrew, Cooper, Cyrus, Javaid, M. K., Hermann, Anne P., Prieto-Alhambra, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448716/
https://www.ncbi.nlm.nih.gov/pubmed/32483674
http://dx.doi.org/10.1007/s11657-020-00746-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448716/
https://www.ncbi.nlm.nih.gov/pubmed/32483674
http://dx.doi.org/10.1007/s11657-020-00746-z

Ejemplares similares